| Literature DB >> 29089818 |
Naira Figueiredo Deana1, Carlos Zaror2,3, Paulo Sandoval2, Nilton Alves4.
Abstract
OBJECTIVES: To assess the effectiveness of low-level laser therapy (LLLT) in reducing orthodontic pain after the application of orthodontic force (OF).Entities:
Mesh:
Year: 2017 PMID: 29089818 PMCID: PMC5635293 DOI: 10.1155/2017/8560652
Source DB: PubMed Journal: Pain Res Manag ISSN: 1203-6765 Impact factor: 3.037
Search strategy and results for PubMed, EMBASE, Cochrane Library, Web of Science, Scopus, and EBSCOhost.
| Database | Search strategy | Results |
|---|---|---|
| MEDLINE/PubMed | # 1: Low-level light therapy [Mesh] OR Low level laser therapy (Pubmed) OR Laser therapy (Pubmed) | 76,795 |
| # 2: Analgesia [Mesh] OR Discomfort (Pubmed) | 76,088 | |
| # 3: Orthodontic | 62,754 | |
| # 4: # 1 AND # 2 AND # 3 | 398 | |
|
| ||
| EMBASE | # 1: Low-level laser therapy | 16,792 |
| # 2: Pain AND tooth pain | 6,559 | |
| # 3: Orthodontics | 60,423 | |
| # 4: controlled clinical trial | 597,953 | |
| # 5: # 1 AND # 2 AND # 3 AND # 4 | 15 | |
|
| ||
| Cochrane Library | # 1: (Low-level light therapy) | 366 |
| # 2: (Pain) | 27,139 | |
| # 3: (Orthodontics OR Orthodontic appliances, OR Orthodontic Anchorage procedures) | 54 | |
| # 4: # 1 AND # 2 AND # 3 | 9 | |
|
| ||
| Web of Science | # 1. low-level laser therapy AND Clinical trial AND Pain AND Orthodontics | 8 |
|
| ||
| Scopus | # l. low-level laser therapy AND Clinical trial AND Pain AND Orthodontics | 19 |
|
| ||
| EBSCOhost | ## 1: Low-level laser therapy OR Laser therapy OR LLLT | 612 |
| # 2: Pain | 13,209 | |
| # 3: Orthodontic treatment | 6,779 | |
| # 4: # 1 AND # 2 AND # 3 | 8 | |
Figure 1Flowchart of systematic literature review.
Summary of laser irradiation parameters used in each study.
| Authors | Subjects | Age | Type of laser/ | SP | ED (J/cm2) | OP (mW) | Points |
| Frequency of laser therapy | TE (J) | Study design | LLLT is |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| ||||||||||||
|
| ||||||||||||
| Abtahi | 29/24 : 5 | 12–22 | GaAs 904 nm, pulsed mode | 0.38 cm2 | NI | 200 mW | 4 points: (cervical and radicular) | 30 s | 0, 1, 2, 3, and 4 | 1.5/point | Single blind, split-mouth | No |
|
| ||||||||||||
| Almallah | 36 | 12–26 | GaAlAs 830 nm | 7 mm | 16/tooth | 100 mW | 8 lingual, 8 palatal | 28 s/area | Single dose and | NI | Single blind, split-mouth | Yes |
|
| ||||||||||||
| AlSayed Hasan | 13/3 : 9 | Mean age | GaAlAs 830 nm, | NI | 2.25/tooth | 150 mW | 2 points: mesial and distal, cervical third | 15 s/point | Single dose | 2/point | Single blind, split-mouth | No |
| 13/4 : 7 | Mean age | GaAlAs 830 nm, | NI | 9/tooth | 150 mW | 2 points: mesial and distal, cervical third | 60 s/point | Single dose | 8/point | Single blind, split-mouth | No | |
|
| ||||||||||||
| Artés-Ribas | 20/06 : 14 | 19–33.8 | GaAlAs 830 nm | 0.4 cm2 | 5/point | 100 mW | 6: 3 vestibular, 3 lingual | 120 s/tooth | Single dose | 2/point, | Single blind, split-mouth | Yes |
|
| ||||||||||||
| Bicakci | 19/08 : 11 | 13.5–14.5 | GaAlAs 820 nm | 0.0314 cm2 | 7.96/point | 50 mW | 4: mesiobuccal mesiopalatal | 5 s/point | 0, 24 h | 0.25/point | Single blind, split-mouth | Yes |
|
| ||||||||||||
| Eslamian | 37/12 : 25 | 11–32 | GaAlAs 810 nm, continuous mode | NI | 2/point | 100 mW | 10: 5 buccal, 5 palatal | 20 s/point | 0, 24 h | NI | Single blind, split-mouth | Yes |
|
| ||||||||||||
| Farias | 30 | 18–40 | GaAlAs 810 nm | 0.028 cm2 | 2/point | 100 mW | 3 points: interdental | 15 s/point | Single dose | 6/tooth | Double blind, | Yes |
|
| ||||||||||||
| Furquim | 79 | 13–34 | GaAlAs 808 nm | NI | 80/tooth | NI | NI | NI | Single dose | 6/tooth | Single blind, split-mouth | No |
|
| ||||||||||||
| Lim | 39 | 21–24 | GaAlAs 830 nm | NI | NI | 30 mW | 1: middle third | 15 s; 30 s; 60 s/tooth | 0, 1, 2, 3, 4, and 5 | 0.45; 0.95; 1.8 | Double blind, split-mouth | No |
|
| ||||||||||||
| Marini | 120/64 : 56 | 20–25 | GaAs 910 nm | 0.5 cm2 | NI | 160 mW | 2: cervical third (buccal and lingual) | 340 s/total | Single dose | 54.4/total energy | Double blind, parallel | Yes |
|
| ||||||||||||
| Nóbrega | 60/22 : 38 | 12–26 | GaAlAs 830 nm | 2 mm | 1/point | 40.6 mW | 4 points (vestibular) | 25/point | Single dose | 5/tooth | Double blind, parallel | Yes |
|
| ||||||||||||
| Qamruddin | 88/28 : 60 | 13–30 | GaAlAs 940 nm, | NI | NI | 200 mW | 3 points buccally: mesial, distal middle | 20 s/point | Single dose | 4/point | Single blind, split-mouth | Yes |
|
| ||||||||||||
|
| ||||||||||||
|
| ||||||||||||
| Bayani | 40 | 14–21 | GaAlAs 810 nm | 0,28 | 3,6/tooth | 200 mW | 6: cervical, middle, apical (vestibular and lingual) | 30 s/tooth | Single dose | 6/tooth | Parallel | Yes |
|
| ||||||||||||
| Deshpande | 30 | 16–25 | GaAs 904 nm | 5 mm | NI | 10 W | Lingual and buccal: middle third region | 120 s/side | Single dose | NI | Single blind, parallel | Yes |
|
| ||||||||||||
| Tortamano | 60/18 : 42 | 12–18 | GaAlAs 830 nm | NI | 5/tooth | 30 mW | 10: 2 apical, 1 middle third, 2 cervical (palatal, lingual) | 16/point | Single dose | NI | Double blind, parallel | Yes |
|
| ||||||||||||
|
| ||||||||||||
|
| ||||||||||||
| Domínguez and | 59/19 : 40 | NI | GaAlAs 830 nm | 600 | 80/point | 100 mW | 2: 1 vestibular, 1 palatal | 44 s/tooth | Single dose | 4.4/tooth | Single blind, split-mouth | Yes |
|
| ||||||||||||
|
| ||||||||||||
|
| ||||||||||||
| Angelieri | 12 | Mean age 12.66 | ArGaAl 780 nm | NI | 5/point | 20 mW | 10 points: 5 buccal and 5 lingual | 10 s/point | 0, 3, and 7 | 0.2/point | Single blind, split-mouth | No |
|
| ||||||||||||
| Dalaie | 12/3 : 9 | Mean age 20.1 | GaAlAs 880 nm, | NI | 5/point | 100 mW | 8 points: | 10 s/point | 1, 3, 7, 30, 33, 37, 60, 63, and 67 | NI | Double blind, split-mouth | No |
|
| ||||||||||||
| Doshi-Mehta and Bhad-Patil [ | 20/8 : 12 | 12–23 | GaAlAs 800 nm, | NI | 5/total | 0.7 mW | 2: 1 buccal | 10 s/point | 0, 3, 7, and 14 (first month and thereafter every 15 days) | 8/tooth | Single blind, split-mouth | Yes |
|
| ||||||||||||
| Heravi | 20/03 : 17 | 15–31 | GaAlAS 810 nm, continuous mode | 0.28 cm2 | 21.4/point | 200 mW | 10 points: 5 buccal and 5 lingual | 30 s/point | 0, 4, 7, 11, 15, 32, 35, 39, 43, and 56 | 6/point | Single blind, split-mouth | No |
M: male, F: female, λ: wavelength, OP: output power, t: time, TE: total energy, ED: energy density, SP: spot size, OT: orthodontic treatment, and NI: not informed.
Description of the principal findings for the control group and the group irradiated with LLLT, with pain assessment method and interval after orthodontic activation.
| Author |
|
|
| Evaluation of pain level | |
|---|---|---|---|---|---|
| Laser group (LG) | Control group (CG)/placebo | ||||
| Abtahi | VAS | Pain levels were measured for 5 days | No statistically | (1) Days 1, 3, 4, and 5: no statistically | (1) The maximum level of pain |
|
| |||||
| Almallah | VAS | 1, 6, 24, 48, and 96 hours | LLLT reduced | (1) Peak pain occurred after 24 hrs in the group which received a single irradiation | |
|
| |||||
| AlSayed Hasan | VAS | 1, 6, 12, 24, 48, and 72 hours | A single application | (1) Peak pain occurred 24 hrs after application of orthodontic force in both the placebo | |
|
| |||||
| Angelieri | VAS | 12, 24, 48, and 72 h after LLLT | The laser protocol | (1) No statistically significant difference in pain reduction was found between the | |
|
| |||||
| Artés-Ribas | VAS | 5 m, 6 h, 24 h, 48 h, and 72 h | The LLLT parameters | (1) Significant pain reduction as compared with | (1) Peak pain in 24 hours. |
|
| |||||
| Bayani | VAS | 2 h, 6 h, bedtime, 24 h, 2, 3, and 7 days | A single irradiation | (1) Peak pain occurred 24 hrs after application of orthodontic force. | |
|
| |||||
| Bicakci | VAS | 5 m, 1 h, 24 h | Significant reduction in | (1) Significant pain reduction was observed | (1) The mean PGE2 levels were |
|
| |||||
| Dalaie | Wong-Baker | Days 1, 33, and 63 | No solid evidence was | (1) There was no statistically significant difference in pain reduction | |
|
| |||||
| Deshpande | Scale used by Tortamano et al. modified (Harazaki + Number Rating Scale) | 1, 24, 48, and 72 h after LLLT | LLLT reduced pain | (1) Peak pain occurred 1 day after | (1) Peak pain occurred 2 |
|
| |||||
| Domínguez and | VAS | 2 h, 6 h, and 24 h | LLLT is effective | (1) Pain was significantly less in the LLLT group at all the intervals | |
|
| |||||
| Doshi-Mehta | VAS | Days: 1, 3, and 30 | Pain level reduced significantly with | (1) Significant pain reduction on days 3 and | (1) Significant pain reduction |
|
| |||||
| Eslamian | VAS | 6 h, 24 h, and 30 h | LLLT reduced pain perception in the | (1) After 6, 24, and 30 h and on day 3 | (1) Pain intensity peaked between |
|
| |||||
| Farias | VAS | 5 min., 24 and 120 hours | AlGaAs diode LLLT | (1) After 24 h a 13.89% reduction in pain | (1) After 24 h there was a 44.39% |
|
| |||||
| Furquim | VAS | 6 h, 12 h | LLLT did not | (1) The pain peak perceived by patients occurred between 12 hours and 1 day. | |
|
| |||||
| Heravi | VAS | Days 0, 4, 7, 11, 15, 28, 32, 35, 39, 43, and 56 | LLLT with the parameters used in | (1) No significant difference was found in VAS scores between the laser and | |
|
| |||||
| Lim | VAS | Before and after LLLT for 5 days | No statistically significant | (1) Pain intensity was lower in the experimental group than in the placebo group; | |
|
| |||||
| Marini | VAS | 0, 12, 24, 36, 48, 72, and 96 h | LLLT is effective | (1) No significant difference between the arches. | |
|
| |||||
| Nóbrega | VAS | 2, 6, 24, 72, 120 hours | Laser irradiation controlled the | (1) The levels of spontaneous and | (1) Two hours after installation of the |
|
| |||||
| Qamruddin | Numerical Rating Scale | 24 hours, for the next 7 days | A single dose of LLLT reduced spontaneous and chewing pain | (1) Peak pain in 24 hours. | (1) Peak pain in 24 hours. |
|
| |||||
| Tortamano | Harazaki + Numeric Rating Scale | Pain start, most painful day, and end of pain | LLLT efficiently controls pain caused by the first archwire | (1) Lower intensity of oral pain compared to the placebo and control groups. | |
Figure 2Risk of bias summary: authors' judgments about each risk of bias item for studies included.
Figure 3Forest plot of pooled standard mean difference in spontaneous pain at 24 hours.
Figure 4Forest plot of pooled standard mean difference in spontaneous pain at 72 hours.
Figure 5Forest plot of pooled standard mean difference in chewing pain at 24 hours.
Figure 6Forest plot of pooled standard mean difference in chewing pain at 72 hours.
GRADE quality evidence.
| Outcomes | N. of participants | Quality of the evidence | Anticipated absolute effects | |
|---|---|---|---|---|
| Risk with placebo | Risk difference with pain laser | |||
| Spontaneous pain 24 h, elastomeric separators | 203 participants |
| — | SMD |
|
| ||||
| Spontaneous pain 24 h, archwire placement | 60 participants |
| — | SMD |
|
| ||||
| Spontaneous pain 72 h, elastomeric separators | 185 participants |
| — | SMD |
|
| ||||
| Spontaneous pain 72 h, archwire placement | 20 participants |
| — | SMD |
|
| ||||
| Chewing pain 24 h, elastomeric separators | 160 participants |
| — | SMD |
|
| ||||
| Chewing pain 72 h, elastomeric separators | 160 participants |
| — | SMD |
CI, confidence interval; SMD, standardised mean difference; GRADE, working group grades of evidence: high quality: we are very confident that the true effect lies close to that of the estimate of the effect; moderate quality: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different; low quality: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect; very low quality: we have very little confidence in the effect estimate, the true effect is likely to be substantially different from the estimate of effect; explanations: athe evidence was downgraded by two levels because of very serious concern regarding the risk of bias; one study had high risk in random sequence generation, two studies did not report information regarding allocation concealment, and two studies had a high risk of performance bias; bthe evidence was downgraded by one level because one study had high risk regarding selective report and small number of participants; cthe evidence was downgraded by two levels because of very serious concern regarding the risk of bias; one study had high risk in random sequence generation, two studies did not report information regarding allocation concealment, and one study had a high risk of performance bias; dthe evidence was downgraded by one level because one study had high risk regarding selective report and one level because it is single study (indirectness); ethe evidence was downgraded by two levels because of very serious concern regarding the risk of bias; one study did not report information regarding allocation concealment and two studies had a high risk of performance bias.